Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis

Journal of Zhejiang University: Science B

Volumn 16, Issue 1, 2015, Pages 1-9

  Zhang, Lei ^a   Wang, Hao ^b   Zhang, Yi qing ^c  

^a Tianjin Joint Academy of Biomedicine and Technology   (China)

^b NANKAI UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON; CYTOKINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; ASYMPTOMATIC INFECTION; CELLULAR IMMUNITY; CYTOKINE STORM; DISEASE SEVERITY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INCUBATION TIME; INNATE IMMUNITY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK; SURVIVAL; T CELL DEPLETION; VIRUS IMMUNITY; VIRUS LOAD; COMPLICATION; EBOLAVIRUS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MORTALITY; VIROLOGY;

EBOLA VIRUS;

ADAPTIVE IMMUNITY; CYTOKINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON TYPE I; MESENCHYMAL STROMAL CELLS; SHOCK, SEPTIC;

EID: 84920829080     PISSN: 16731581     EISSN: 18621783     Source Type: Journal    
DOI: 10.1631/jzus.B1400365     Document Type: Article

References (33)

1. Ansari, A.A., 2014. Clinical features and pathobiology of Ebolavirus infection. J. Autoimmun., 55:1–9. [doi:10.1016/j.jaut.2014.09.001]
2. Baize, S., Leroy, E.M., Georges-Courbot, M.C., et al., 1999. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med., 5(4):423–426. [doi:10.1038/7422]
3. Baize, S., Leroy, E.M., Georges, A.J., et al., 2002. Inflammatory responses in Ebola virus-infected patients. Clin. Exp. Immunol., 128(1):163–168. [doi:10.1046/j.1365-2249.2002.01800.x]
4. Baxter, A.G., 2000. Symptomless infection with Ebola virus. Lancet, 355(9222):2178–2179. [doi:10.1016/S0140-6736(00)02394-1]
5. Bray, M., Mahanty, S., 2003. Ebola hemorrhagic fever and septic shock. J. Infect. Dis., 188(11):1613–1617. [doi:10.1086/379727]
6. Cao, L., Zhang, L., Tian, L., et al., 2011. Antivirus evaluation and clinical evaluation of recombinant human interferon α2b spray. Chin. Med. Biotechnol., 6(5):336–340 (in Chinese). [doi:10.3969/cmba.j.issn.1673-713X.2011.05.004]
7. Cárdenas, W.B., Loo, Y.M., Gale, M., et al., 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol., 80(11):5168–5178. [doi:10.1128/JVI.02199-05]
8. Fowler, R.A., Fletcher, T., Fischer, W.A., et al., 2014. Caring for critically ill patients with Ebola virus disease. Perspectives from West Africa. Am. J. Respir. Crit. Care Med., 190(7): 733–737. [doi:10.1164/rccm.201408-1514CP]
9. Geisbert, T.W., Hensley, L.E., Gibb, T.R., et al., 2000. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab. Invest., 80(2):171–186. [doi:10.1038/labinvest.3780021]
10. Hoenen, T., Groseth, A., Falzarano, D., et al., 2006. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol. Med., 12(5):206–215. [doi:10.1016/j.molmed.2006.03.006]
11. Ivashkiv, L.B., Donlin, L.T., 2014. Regulation of type I interferon responses. Nat. Rev. Immunol., 14(1):36–49. [doi:10.1038/nri3581]
12. Jahrling, P.B., Geisbert, T.W., Geisbert, J.B., et al., 1999. Evaluation of immune globulin and recombinant interferon-α2b for treatment of experimental Ebola virus infections. J. Infect. Dis., 179(s1):S224–S234. [doi:10.1086/514310]
13. Kebriaei, P., Isola, L., Bahceci, E., 2009. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol. Blood Marrow Transpl., 15(7):804–811. [doi:10.1016/j.bbmt.2008.03.012]
14. Ksiazek, T.G., Rollin, P.E., Williams, A.J., et al., 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis., 179(S1):S177–S187. [doi:10.1086/514321]
15. le Bon, A., Tough, D.F., 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol., 14(4):432–436. [doi:10.1016/S0952-7915(02)00354-0]
16. Leroy, E.M., Baize, S., Volchkov, V.E., et al., 2000. Human asymptomatic Ebola infection and strong inflammatory response. Lancet, 355(9222):2210–2215. [doi:10.1016/S0140-6736(00)02405-3]
17. Leroy, E.M., Baize, S., Debre, P., et al., 2001. Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Immunol., 124(3):453–460. [doi:10.1046/j.1365-2249.2001.01517.x]
18. Misasi, J., Sullivan, N.J., 2014. Camouflage and misdirection: the full-on assault of Ebola virus disease. Cell, 159(3): 477–486. [doi:10.1016/j.cell.2014.10.006]
19. Mohamadzadeh, M., Chen, L., Schmaljohn, A.L., 2007. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol., 7(7):556–567. [doi:10.1038/nri2098]
20. Pedrazza, L., Lunardelli, A., Luft, C., et al., 2014. Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. Inflamm. Res., 63(9):719–729. [doi:10.1007/s00011-014-0745-1]
21. Plock, J.A., Schnider, J.T., Solari, M.G., et al., 2013. Perspectives on the use of mesenchymal stem cells in vascularized composite allotransplantation. Front. Immunol., 4:175. [doi:10.3389/fimmu.2013.00175]
22. Schieffelin, J.S., Shaffer, J.G., Goba, A., et al., 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N. Engl. J. Med., 371(22):2092–2100. [doi:10.1056/NEJMoa1411680]
23. Smith, L.M., Hensley, L.E., Geisbert, T.W., et al., 2013. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis., 208(2):310–318. [doi:10.1093/infdis/jis921]
24. Stolzing, A., Jones, E., McGonagle, D., et al., 2008. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech. Ageing Dev., 129(3):163–173. [doi:10.1016/j.mad.2007.12.002]
25. Sullivan, N., Yang, Z.Y., Nabel, G.J., 2003. Ebola virus pathogenesis: implications for vaccines and therapies. J. Virol., 77(18):9733–9737. [doi:10.1128/JVI.77.18.9733-9737.2003]
26. Sun, L., Akiyama, K., Zhang, H., et al., 2009. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells, 27(6):1421–1432. [doi:10.1002/stem.68]
27. Toledano, H., D’Alterio, C., Czech, B., 2012. The let-7-Imp axis regulates ageing of the Drosophila testis stem-cell niche. Nature, 485(7400):605–610. [doi:10.1038/nature 11061]
28. Tyndall, A., Pistoia, V., 2009. Mesenchymal stem cells combat sepsis. Nat. Med., 15(1):18–20. [doi:10.1038/nm0109-18]
29. Wang, Y., Chen, X., Cao, W., et al., 2014. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat. Immunol., 15(11): 1009–1016. [doi:10.1038/ni.3002]
30. Wannemuehler, T.J., Manukyan, M.C., Brewster, B.D., et al., 2012. Advances in mesenchymal stem cell research in sepsis. J. Surg. Res., 173(1):113–126. [doi:10.1016/j.jss.2011.09.053]
31. Wauquier, N., Becquart, P., Padilla, C., et al., 2010. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis., 4(10):e837. [doi:10.1371/journal.pntd.0000837]
32. Xu, W., Edwards, M.R., Borek, D.M., et al., 2014. Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1. Cell Host Microbe, 16(2): 187–200. [doi:10.1016/j.chom.2014.07.008]
33. Zhang, L., Wang, H., 2014. Forty years of the war against Ebola. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(9):761–765. [doi:10.1631/jzus.B1400222]